Matches in Wikidata for { <http://www.wikidata.org/entity/Q58485593> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- Q58485593 description "article" @default.
- Q58485593 description "im Mai 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q58485593 description "wetenschappelijk artikel" @default.
- Q58485593 description "наукова стаття, опублікована в травні 2018" @default.
- Q58485593 name "First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison" @default.
- Q58485593 name "First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison" @default.
- Q58485593 type Item @default.
- Q58485593 label "First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison" @default.
- Q58485593 label "First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison" @default.
- Q58485593 prefLabel "First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison" @default.
- Q58485593 prefLabel "First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison" @default.
- Q58485593 P1433 Q58485593-D7E85626-7880-48A3-BACE-0FBB3B9D3CD8 @default.
- Q58485593 P1476 Q58485593-890337E0-5DC2-4C8F-90FC-5AD0809868D6 @default.
- Q58485593 P2093 Q58485593-022DB3F7-E97E-40DF-A681-14836E7823EA @default.
- Q58485593 P2093 Q58485593-0290BF68-73AD-4ECC-996B-EB7ACBD9656D @default.
- Q58485593 P2093 Q58485593-9534D3B9-3F34-484C-BE1F-3C59FD9E4801 @default.
- Q58485593 P2093 Q58485593-AB97FEDB-EE43-41B5-98F8-49CBF650FEAE @default.
- Q58485593 P2093 Q58485593-B5836610-F7C1-4795-A408-12F4D6404ACA @default.
- Q58485593 P2093 Q58485593-CEC862BB-F89E-4B1C-B58B-C7268E9EBCC3 @default.
- Q58485593 P2093 Q58485593-D23D1D26-DD41-459E-A759-F4E743B46D14 @default.
- Q58485593 P2093 Q58485593-D7A31C74-75F3-4951-B6F5-FABA12B8665E @default.
- Q58485593 P2093 Q58485593-EB4AA92D-DCDE-400D-8A6F-2024D1961825 @default.
- Q58485593 P304 Q58485593-5A843631-864F-4AEB-8206-571367EFBE9C @default.
- Q58485593 P31 Q58485593-B4596891-3C8E-46E1-9029-1F12CF5C8CAE @default.
- Q58485593 P356 Q58485593-00A71FC9-5A78-4B31-B34C-A1B7ED1AD10B @default.
- Q58485593 P433 Q58485593-E1F837CC-8B0E-4D65-955E-31401C6E6D72 @default.
- Q58485593 P478 Q58485593-603E0660-5723-42E0-97E6-371710566081 @default.
- Q58485593 P50 Q58485593-29A63B08-7DBD-4D25-A6E3-126E35A8F278 @default.
- Q58485593 P50 Q58485593-AF1D4830-A5DE-4AE0-8956-28192E67B58D @default.
- Q58485593 P50 Q58485593-BAD2EC0C-9BBF-4AD0-AFF7-0A320C03D3C8 @default.
- Q58485593 P50 Q58485593-E16B84B8-3AB0-48F8-8077-0FE89DEFA75B @default.
- Q58485593 P577 Q58485593-6B6AD026-CA94-4EFC-B338-CEE9AAF66B5D @default.
- Q58485593 P698 Q58485593-BE0B2493-6F36-4385-9CD6-CBF2C650B2FC @default.
- Q58485593 P921 Q58485593-3BE3668B-0FF9-48C9-83D9-ADF4D435D2A3 @default.
- Q58485593 P921 Q58485593-6DD37C46-E424-4FA1-937E-FA4DB49D940A @default.
- Q58485593 P921 Q58485593-6E27FA8B-BDD1-4458-95E4-63DD3086FCD2 @default.
- Q58485593 P921 Q58485593-8B05471F-C53C-400B-808B-B72D90ADDE39 @default.
- Q58485593 P921 Q58485593-E5F1C59B-0B48-4A38-9B43-27747C0D6DC3 @default.
- Q58485593 P356 HIV.12628 @default.
- Q58485593 P698 29846042 @default.
- Q58485593 P1433 Q15756376 @default.
- Q58485593 P1476 "First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison" @default.
- Q58485593 P2093 "A Cozzi-Lepri" @default.
- Q58485593 P2093 "A Tavelli" @default.
- Q58485593 P2093 "C Viscoli" @default.
- Q58485593 P2093 "F Maggiolo" @default.
- Q58485593 P2093 "Italian Cohort Naive Antiretrovirals (ICONA) Foundation Study Group" @default.
- Q58485593 P2093 "M Zaccarelli" @default.
- Q58485593 P2093 "P Caramello" @default.
- Q58485593 P2093 "S Bonora" @default.
- Q58485593 P2093 "S Lo Caputo" @default.
- Q58485593 P304 "475-484" @default.
- Q58485593 P31 Q13442814 @default.
- Q58485593 P356 "10.1111/HIV.12628" @default.
- Q58485593 P433 "7" @default.
- Q58485593 P478 "19" @default.
- Q58485593 P50 Q41372289 @default.
- Q58485593 P50 Q42206554 @default.
- Q58485593 P50 Q56379537 @default.
- Q58485593 P50 Q59189147 @default.
- Q58485593 P577 "2018-05-30T00:00:00Z" @default.
- Q58485593 P698 "29846042" @default.
- Q58485593 P921 Q1519812 @default.
- Q58485593 P921 Q155954 @default.
- Q58485593 P921 Q18123741 @default.
- Q58485593 P921 Q422604 @default.
- Q58485593 P921 Q422645 @default.